A third patient participating in Audentes Therapeutics, Inc.’s Phase I/II ASPIRO clinical trial evaluating the gene therapy resamirigene bilparvovec (AT132) in patients with X-linked myotubular myopathy (XLMTM) has died, taking to three the number of deaths in the study.
The San Francisco-based company, acquired by Japan’s Astellas Pharma, Inc. for $3bn late last year, said that preliminary findings...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)